[Ip-health] WHA71: KEI intervention on Addressing the global shortage of, and access to, medicines and vaccines

Thiru Balasubramaniam thiru at keionline.org
Sun May 20 23:33:04 PDT 2018


https://www.keionline.org/27884

KEI intervention on Addressing the global shortage of, and access to,
medicines and vaccines

21 May 2018
Knowledge Ecology International (KEI) intends to deliver the following
statement on Addressing the global shortage of, and access to, medicines
and vaccines: 11.5 Addressing the global shortage of, and access to,
medicines and vaccines

The Road Map report is WHO’s work program on access to medicines and
vaccines which deals with issues that have several dimensions, including at
the center, the global set of incentives and funding mechanisms for
research and development to simulate the development of new drugs,
vaccines, diagnostics and new cell and gene therapies.

To evaluate the impact of the current system and any proposed reforms, both
incremental and transformative, on innovation and access, the twin and
currently conflicting objectives, it is important to have better evidence
regarding the costs of R&D of specific products and services, in a level of
disaggregation sufficient to adequately analyze the risks associated with
development. It is also important to have better and more transparent
information on resource flows by research targets, data on actual access by
country, the annual and cumulative revenue from sales, as well as greater
transparency and better information on a host of other issues, such as
prices, patent and registration landscapes, the use of exceptions and
limitations to intellectual property rights, the texts of proposed trade
agreements that are relevant to innovation and access to medical
technologies.

There is a need to fix the current failures to obtain competition for
biologic drugs. Recent data in the US show that biologic drugs first
registered between 1995 and 2005 faced competition for products with the
same pharmaceutical active agreement only 17 percent of the time, compared
to 61 percent for small molecules, and when competition did occur, it
happened 6 years later, and only resulted in an average of 1.5 competitors.

Finally, we must admit that we cannot effectively regulate big drug
monopolies in the public interest, and it is time to advance work on the
delinkage of R&D funding including incentives from the prices of goods and
services.


-- 
Thiru Balasubramaniam
Geneva Representative
Knowledge Ecology International
41 22 791 6727
thiru at keionline.org


More information about the Ip-health mailing list